【翰宇药业:与碳云智肽签署《GLP-1R/GIPR/GCGR三重激动剂多肽创新药物联合开发协议》】金十数据5月12日讯,翰宇药业公告,公司与深圳碳云智肽药物科技有限公司签署了《GLP-1R/GIPR/GCGR三重激动剂多肽创新药物联合开发协议》。双方将共同开发多肽创新药物,应用于体重控制等代谢性疾病治疗领域。根据协议,翰宇药业将负责临床前研究、IND申报、临床试验及产品注册申报,并承担相应费用。碳云智肽负责分子筛选,并承担筛选过程中的所有开发费用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.